Remove Aortic valve Remove Stenosis Remove TAVR
article thumbnail

Optimal antithrombotic therapy after transcatheter aortic valve replacement: a comprehensive review

Frontiers in Cardiovascular Medicine

Transcatheter aortic valve replacement (TAVR) has become a leading treatment for aortic stenosis, but managing thromboembolic and bleeding risks post-procedure remains challenging. This review examines current evidence on antithrombotic therapy after TAVR.

article thumbnail

TAVR System Shows Durable Clinical Outcomes, Strong Valve Performance in Low-Risk Aortic Stenosis Patients

DAIC

Data shows, versus surgery, the Evolut transcatheter aortic valve replacement (TAVR) system delivers a numerically lower rate of all-cause mortality or disabling stroke at five years, strong valve performance and durable clinical outcomes. Evolut TAVR vs. 9.3% Evolut TAVR vs. 9.3% Grubb, M.D., 1 Herrmann H.

TAVR 52
article thumbnail

Major Win for Preemptive TAVR in Symptomless Aortic Stenosis

Med Page Today

(MedPage Today) -- Transcatheter aortic valve replacement (TAVR) yielded clinical benefit when given early in the disease process while patients still had no symptoms or other indication for aortic valve replacement, according to the EARLY TAVR.

TAVR 105
article thumbnail

Early experience with a novel transapical transcatheter aortic valve system in patients with severe aortic stenosis: a prospective, multicenter study

Frontiers in Cardiovascular Medicine

ObjectivesRegistered, prospective, multicenter study of the short-term clinical outcomes of a novel transcatheter aortic valve system (Xcor system, Saint Medical Technology, Inc.,

article thumbnail

Almost 50% of Patients Under 60 Years Choose TAVR Over Surgical Aortic Valve Replacement with Worse Outcomes

DAIC

Getty Images milla1cf Mon, 01/29/2024 - 14:24 January 29, 2024 — Despite national guidelines recommending surgical aortic valve replacement (SAVR) for patients under age 65 with severe aortic stenosis , many hospitals are still opting for a nonsurgical approach in patients under 60—possibly with poorer survival rates.

article thumbnail

Valvular and perivalvular thrombus after TAVR: Risks and Outcomes

Cardiology Update

Transcatheter aortic valve replacement (TAVR) is the standard treatment for severe aortic stenosis, but post-TAVR leaflet thrombus, identified by hypoattenuated leaflet thickening (HALT), poses potential risks like cerebral thromboembolic events. had thrombus at any aortic valve complex.

TAVR 122
article thumbnail

Medtronic Announces FDA Approval of Newest-generation Evolut TAVR System for Treatment of Symptomatic Severe Aortic Stenosis

DAIC

milla1cf Thu, 03/28/2024 - 07:30 March 28, 2024 — Medtronic plc, a global leader in healthcare technology, announced that the United States Food and Drug Administration ( FDA ) has approved the Evolut FX+ transcatheter aortic valve replacement (TAVR) system for the treatment of symptomatic severe aortic stenosis.

TAVR 111